<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Spyre Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/spyre-therapeutics-inc</link>
<description>Latest news and press releases for Spyre Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 05 May 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/spyre-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c62c78dffbe2df11aea3.webp</url>
<title>Spyre Therapeutics, Inc.</title>
<link>https://6ix.com/company/spyre-therapeutics-inc</link>
</image>
<item>
<title>Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 05 May 2026 12:00:00 GMT</pubDate>
<description>Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the rheumatoid arthritis (“RA”) sub-study of the Phase 2 SKYWAY basket trial Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Further strengthened the balance sh</description>
</item>
<item>
<title>Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-gross-proceeds-of-dollar4635-million</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-gross-proceeds-of-dollar4635-million</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-pricing-of-upsized-dollar4030-million-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-pricing-of-upsized-dollar4030-million-public-offering-of-common-stock</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Therapeutics Announces Proposed Public Offering of its Common Stock</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-proposed-public-offering-of-its-common-stock</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-announces-potential-best-in-class-spy001-part-a-induction-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points</description>
</item>
<item>
<title>Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-to-host-conference-call-to-report-spy001-part-a-induction-topline-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients-on-april-13-2026</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-to-host-conference-call-to-report-spy001-part-a-induction-topline-results-from-skyline-trial-in-moderate-to-severe-ulcerative-colitis-patients-on-april-13-2026</guid>
<pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting</description>
</item>
<item>
<title>Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-announces-acceleration-of-expected-topline-readout-of-skyway-rheumatoid-arthritis-sub-study-to-q3-2026</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-announces-acceleration-of-expected-topline-readout-of-skyway-rheumatoid-arthritis-sub-study-to-q3-2026</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for</description>
</item>
<item>
<title>Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 19 Feb 2026 21:02:00 GMT</pubDate>
<description>On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial spondyloarthritis ("axSpA"), with fourth quarter readouts expected in each sub-study Strengthened</description>
</item>
<item>
<title>Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-presentations-at-the-21st-ecco-congress-supporting-differentiated-profile-of-spy003-and-novel-animal-studies-demonstrating-superiority-of-combination-approach</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-presentations-at-the-21st-ecco-congress-supporting-differentiated-profile-of-spy003-and-novel-animal-studies-demonstrating-superiority-of-combination-approach</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced scientific presentations at the 21st Congress of the European Crohn’s and Colitis Organisation (ECCO), held February 18-21, 2026 in Stockholm, Sweden. “We are excited to share follow-up data out to</description>
</item>
<item>
<title>Spyre Therapeutics Announces Grants of Inducement Awards</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-grants-inducement-210100429</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-grants-inducement-210100429</guid>
<pubDate>Fri, 06 Feb 2026 21:01:00 GMT</pubDate>
<description>WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 30,200 shares of common stock of Spyre to</description>
</item>
<item>
<title>Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-poised-transformational-2026-six-expected-proof-concept-readouts</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-poised-transformational-2026-six-expected-proof-concept-readouts</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>“6 in ’26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than</description>
</item>
<item>
<title>Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an</description>
</item>
<item>
<title>Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-positive-interim-phase-1-results-spy003-its-novel-half</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-positive-interim-phase-1-results-spy003-its-novel-half</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim</description>
</item>
<item>
<title>Spyre Therapeutics to Participate in Upcoming November Investor Conferences</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-participate-upcoming-november-investor-conferences-2025-10-29</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-participate-upcoming-november-investor-conferences-2025-10-29</guid>
<pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting</description>
</item>
<item>
<title>Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-poster-presentations-american-college-rheumatology-acr</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-poster-presentations-american-college-rheumatology-acr</guid>
<pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting</description>
</item>
<item>
<title>Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-inc-announces-closing-public-offering-and-full-exercise</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-inc-announces-closing-public-offering-and-full-exercise</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-pricing-2750-million-public-offering-common-stock-2025</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-pricing-2750-million-public-offering-common-stock-2025</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-proposed-public-offering-its-common-stock-and-pre-funded</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-proposed-public-offering-its-common-stock-and-pre-funded</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company</description>
</item>
<item>
<title>Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-poster-presentations-united-european-gastroenterology</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-announces-poster-presentations-united-european-gastroenterology</guid>
<pubDate>Sun, 05 Oct 2025 04:00:00 GMT</pubDate>
<description>WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class</description>
</item>
<item>
<title>Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases</title>
<link>https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-doses-first-patient-pioneering-phase-2-skyway-basket-trial-spy072</link>
<guid isPermaLink="true">https://6ix.com/company/spyre-therapeutics-inc/news/spyre-therapeutics-doses-first-patient-pioneering-phase-2-skyway-basket-trial-spy072</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>SPY072 is a potential first- and best-in-class anti-TL1A antibody for rheumatic diseases targeting quarterly or twice-yearly subcutaneous dosing SKYWAY study</description>
</item>
</channel>
</rss>